Micturition symptoms in gynecologic cancer patients receiving paclitaxel and platinum-based chemotherapy regimen: a prospective study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveTo evaluate the effect of paclitaxel and platinum-based chemotherapy (PT) on micturition symptoms. MethodsAll gynecologic cancer patients who were assigned to receive the PT regimen and understood the Thai languagewere invited to participate in this study. The exclusion criteria were as follows: abnormal urinary symptoms, retainedurinary catheter or percutaneous nephrostomy, anticholinergic drug use, or scheduled to receive radiation therapyafter the completion of chemotherapy. The participants were interviewed using three Thai validated questionnaires,the incontinence impact questionnaire-short form, urogenital distress inventory short form, and Sandvik score, onthe day before receiving the first cycle of chemotherapy (pre-treatment), on the day before receiving the 4th cycle(mid-treatment), and 46 weeks after completing 69 cycles (post-treatment). The scores at the three time points werecompared. Patients who received less than three cycles were not included in the analysis. ResultsOne hundred and ten patients were included in this study. There were significant differences in the medianquestionnaire scores at the three time points for both carboplatin plus paclitaxel and cisplatin plus paclitaxel. However, when using a pairwise difference between the two treatment protocols, there were no significant changesin the score from pre-treatment to post-treatment. ConclusionThe PT regimen has an impact on micturition symptoms during chemotherapy which recover after treatmentcompletion.
Abstract
ObjectiveTo evaluate the effect of paclitaxel and platinum-based chemotherapy (PT) on micturition symptoms. MethodsAll gynecologic cancer patients who were assigned to receive the PT regimen and understood the Thai languagewere invited to participate in this study. The exclusion criteria were as follows: abnormal urinary symptoms, retainedurinary catheter or percutaneous nephrostomy, anticholinergic drug use, or scheduled to receive radiation therapyafter the completion of chemotherapy. The participants were interviewed using three Thai validated questionnaires,the incontinence impact questionnaire-short form, urogenital distress inventory short form, and Sandvik score, onthe day before receiving the first cycle of chemotherapy (pre-treatment), on the day before receiving the 4th cycle(mid-treatment), and 46 weeks after completing 69 cycles (post-treatment). The scores at the three time points werecompared. Patients who received less than three cycles were not included in the analysis. ResultsOne hundred and ten patients were included in this study. There were significant differences in the medianquestionnaire scores at the three time points for both carboplatin plus paclitaxel and cisplatin plus paclitaxel. However, when using a pairwise difference between the two treatment protocols, there were no significant changesin the score from pre-treatment to post-treatment. ConclusionThe PT regimen has an impact on micturition symptoms during chemotherapy which recover after treatmentcompletion.
참고문헌 (14)
- Chan JK, "Metastatic gynecologic malignancies : advances in treatment and management", Clin Exp Metastasis, 35, pp.521~533 (2018)
- Staff NP, "Pathogenesis of paclitaxel-induced peripheral neuropathy : a current review of in vitro and in vivo findings using rodent and human model systems", Exp Neurol, 324, pp.113121~ (2020)
- Lee JJ, "Peripheral neuropathy induced by microtubule-stabilizing agents", J Clin Oncol, 24, pp.1633~1642 (2006)
- Santos NAGD, "Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents", Food Chem Toxicol, 136, pp.111079~ (2020)
- Freeman R, "Autonomic peripheral neuropathy", Neurol Clin, 25, pp.277~301 (2007)
- 조옥희, "Factors Influencing Lower Urinary Tract Symptoms in Advanced Cancer Patients With Chemotherapy-Induced Peripheral Neuropathy", International Neurourology Journal, 22(3), pp.192~199 (2018), 대한배뇨장애요실금학회
- Strauchon CJ, "Urinary symptoms in women receiving carboplatin", paclitaxel for treatment of gynecologic cancers, 2020, pp.30, 1418~1423
- Weerasopone S, "Validation of the Thai version of the incontinence impact questionnaire(IIQ-7)and the urogenital distress inventory(UDI-6)", Chula Med J, 60, pp.389~398 (2016)
- Sandvik H, "A severity index for epidemiological surveys of female urinary incontinence : comparison with 48-hour pad-weighing tests", Neurourol Urodyn, 19, pp.137~145 (2000)
- Hozo SP, "Estimating the mean and variance from the median, range, and the size of a sample", BMC Med Res Methodol, 5, pp.13~ (2005)
- Faul F, "G*Power 3 : a flexible statistical power analysis program for the social, behavioral, and biomedical sciences", Behav Res Methods, 39, pp.175~191 (2007)
- Min Kyeong Kim, "Surgical outcomes of tension-free vaginal tape (TVT)- abbrevo® and TVT-obturator® for the treatment of stress urinary incontinence: a retrospective study", Obstetrics & Gynecology Science, 64(6), pp.540~546 (2021), 대한산부인과학회
- Person F, "Bevacizumab-associated glomerular microangiopathy", Mod Pathol, 32, pp.684~700 (2019)
- Gornstein E, "The paradox of paclitaxel neurotoxicity : mechanisms and unanswered questions", Neuropharmacology, 76(Pt A), pp.175~183 (2014)